{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:23:24Z","timestamp":1781079804010,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>\nIn genetic aortopathies (GA) particular attention is paid to aortic root\u00a0dilatation\u00a0which has an impact on morbidity and mortality. This study focuses on the effects\u00a0of therapy with angiotensin-II-receptor-blockers (ARB) or beta-blockers (BB) on aortic root growth and the question which therapy should be initiated at which dosage and at what age.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\nSince 1998 we diagnosed 208 patients with GA (170 FBN-1). 81 patients between 5\u00a0months and 18\u00a0years receiving either ARB or BB therapy were included. We retrospectively analyzed the progression of the dilatation of Sinus Valsalva aortae (SV) using calculated z-scores before and after therapy initiation and compared BB and ARB treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both ARB and BB (p\u2009&lt;\u20090.05) therapy showed significant improvement in aortic root growth, while the effect is significantly more pronounced in ARB (p\u2009&lt;\u20090.01) independent of age and genetic cause. A detailed comparison of the two drug groups showed a more sustained effect in limiting the progression of the dilatation of the aortic root in patients treated with ARB. Progression of dilatation of the SV was significantly lower in children treated with ARBs compared to BB (delta z-score, p\u2009&lt;\u20090.05). In addition, ARBs were better tolerated and had a significantly lower discontinuation rate (3%) compared to BB (50%) (p\u2009&lt;\u20090.01). Independently of age at initiation all children and adolescents were able to reach the target dose under ARB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>\nWe demonstrated a significant change in both treatment options, with the effect of ARB being more pronounced while being better tolerated throughout the treatment period.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-023-02221-4","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:21:44Z","timestamp":1683768104000},"page":"1610-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prophylactic effect of angiotensin receptor blockers in children with genetic aortopathies: the early bird catches the worm"],"prefix":"10.1007","volume":"112","author":[{"given":"J.","family":"Olfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Kanitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. C.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"von Kodolitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kozlik-Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-5187","authenticated-orcid":false,"given":"T. S.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"6333","key":"2221_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/352337a0","volume":"352","author":"HC Dietz","year":"1991","unstructured":"Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352(6333):337\u2013339. https:\/\/doi.org\/10.1038\/352337a0","journal-title":"Nature"},{"issue":"1","key":"2221_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1477-5751-11-9","volume":"11","author":"KK Singh","year":"2012","unstructured":"Singh KK, Schmidtke J, Keyser B, Arslan-Kirchner M (2012) TGFBR3 variation is not a common cause of Marfan-like syndrome and Loeys-Dietz-like syndrome. J Negat Results Biomed 11(1):9. https:\/\/doi.org\/10.1186\/1477-5751-11-9","journal-title":"J Negat Results Biomed"},{"issue":"15","key":"2221_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/hrt.2010.212100","volume":"97","author":"G Jondeau","year":"2011","unstructured":"Jondeau G, Michel JB, Boileau C (2011) The translational science of Marfan syndrome. Heart Br Card Soc 97(15):1206\u20131214. https:\/\/doi.org\/10.1136\/hrt.2010.212100","journal-title":"Heart Br Card Soc"},{"issue":"9501","key":"2221_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(05)67789-6","volume":"366","author":"DP Judge","year":"2005","unstructured":"Judge DP, Dietz HC (2005) Marfan\u2019s syndrome. Lancet Lond Engl 366(9501):1965\u20131976. https:\/\/doi.org\/10.1016\/S0140-6736(05)67789-6","journal-title":"Lancet Lond Engl"},{"key":"2221_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.suppl_1.1799","author":"H Dietz","year":"1995","unstructured":"Dietz H, Pyeritz R (1995) Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/4.suppl_1.1799","journal-title":"Hum Mol Genet"},{"issue":"15","key":"2221_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJM197204132861502","volume":"286","author":"JL Murdoch","year":"1972","unstructured":"Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA (1972) Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 286(15):804\u2013808. https:\/\/doi.org\/10.1056\/NEJM197204132861502","journal-title":"N Engl J Med"},{"issue":"14","key":"2221_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1056\/NEJM197904053001406","volume":"300","author":"RE Pyeritz","year":"1979","unstructured":"Pyeritz RE, McKusick VA (1979) The Marfan syndrome: diagnosis and management. The N Engl J Med 300(14):772\u2013777. https:\/\/doi.org\/10.1056\/NEJM197904053001406","journal-title":"The N Engl J Med"},{"issue":"4","key":"2221_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00246-012-0593-0","volume":"34","author":"GC Mueller","year":"2013","unstructured":"Mueller GC, Stark V, Steiner K, von Kodolitsch Y, Rybczynski M, Weil J, Mir TS (2013) Impact of age and gender on cardiac pathology in children and adolescents with Marfan syndrome. Pediatr Cardiol 34(4):991\u2013998. https:\/\/doi.org\/10.1007\/s00246-012-0593-0","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"2221_CR9","first-page":"123","volume":"129","author":"BL Halpern","year":"1971","unstructured":"Halpern BL, Char F, Murdoch JL, Horton WB, McKusick VA (1971) A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J 129(3):123\u2013129","journal-title":"Johns Hopkins Med J"},{"issue":"1","key":"2221_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cjca.2015.11.003","volume":"32","author":"MN Singh","year":"2016","unstructured":"Singh MN, Lacro RV (2016) Recent clinical drug trials evidence in marfan syndrome and clinical implications. Can J Cardiol 32(1):66\u201377. https:\/\/doi.org\/10.1016\/j.cjca.2015.11.003","journal-title":"Can J Cardiol"},{"issue":"14","key":"2221_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199010043231409","volume":"323","author":"RE Pyeritz","year":"1990","unstructured":"Pyeritz RE (1990) Marfan syndrome. N Engl J Med 323(14):987\u2013989. https:\/\/doi.org\/10.1056\/NEJM199010043231409","journal-title":"N Engl J Med"},{"issue":"19","key":"2221_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","volume":"330","author":"J Shores","year":"1994","unstructured":"Shores J, Berger KR, Murphy EA, Pyeritz RE (1994) Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan\u2019s syndrome. N Engl J Med 330(19):1335\u20131341. https:\/\/doi.org\/10.1056\/NEJM199405123301902","journal-title":"N Engl J Med"},{"issue":"5770","key":"2221_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117\u2013121. https:\/\/doi.org\/10.1126\/science.1124287","journal-title":"Science"},{"issue":"3","key":"2221_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/heartjnl-2013-304946","volume":"100","author":"GC Mueller","year":"2014","unstructured":"Mueller GC, Stierle L, Stark V, Steiner K, von Kodolitsch Y, Weil J, Mir TS (2014) Retrospective analysis of the effect of angiotensin II receptor blocker versus \u03b2-blocker on aortic root growth in paediatric patients with Marfan syndrome. Heart 100(3):214\u2013218. https:\/\/doi.org\/10.1136\/heartjnl-2013-304946","journal-title":"Heart"},{"issue":"3","key":"2221_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00246-021-02761-4","volume":"43","author":"C Pees","year":"2022","unstructured":"Pees C, Heno J, Michel-Behnke I (2022) Initial angiotensin receptor blocker response in young marfan patients decreases after 3 years of treatment. Pediatr Cardiol 43(3):586\u2013595. https:\/\/doi.org\/10.1007\/s00246-021-02761-4","journal-title":"Pediatr Cardiol"},{"issue":"43","key":"2221_CR16","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1093\/eurheartj\/ehaa377","volume":"41","author":"MM van Andel","year":"2020","unstructured":"van Andel MM, Indrakusuma R, Jalalzadeh H, Balm R, Timmermans J, Scholte AJ, van den Berg MP, Zwinderman AH, Mulder BJM, de Waard V, Groenink M (2020) Long-term clinical outcomes of losartan in patients with Marfan syndrome: Follow-up of the multicentre randomized controlled COMPARE trial. Eur Heart J 41(43):4181\u20134187. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa377","journal-title":"Eur Heart J"},{"issue":"9","key":"2221_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.amjcard.2013.06.019","volume":"112","author":"C Pees","year":"2013","unstructured":"Pees C, Laccone F, Hagl M, DeBrauwer V, Moser E, Michel-Behnke I (2013) Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol 112(9):1477\u20131483. https:\/\/doi.org\/10.1016\/j.amjcard.2013.06.019","journal-title":"Am J Cardiol"},{"issue":"22","key":"2221_CR18","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","volume":"371","author":"RV Lacro","year":"2014","unstructured":"Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Mahony L (2014) Atenolol versus losartan in children and young adults with Marfan\u2019s Syndrome. N Engl J Med 371(22):2061\u20132071. https:\/\/doi.org\/10.1056\/NEJMoa1404731","journal-title":"N Engl J Med"},{"issue":"14","key":"2221_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","volume":"72","author":"G Teixido-Tura","year":"2018","unstructured":"Teixido-Tura G, Forteza A, Rodr\u00edguez-Palomares J, Gonz\u00e1lez Mirelis J, Guti\u00e9rrez L, S\u00e1nchez V, Ib\u00e1\u00f1ez B, Garc\u00eda-Dorado D, Evangelista A (2018) Losartan versus atenolol for prevention of aortic dilation in patients with marfan syndrome. J Am Coll Cardiol 72(14):1613\u20131618. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.052","journal-title":"J Am Coll Cardiol"},{"issue":"10216","key":"2221_CR20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/S0140-6736(19)32518-8","volume":"394","author":"M Mullen","year":"2019","unstructured":"Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D, Kiotsekoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan L, Thomson JDR, Erdem G, Crossman D, Flather M, Investigators AIMS (2019) Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet Lond Engl 394(10216):2263\u20132270. https:\/\/doi.org\/10.1016\/S0140-6736(19)32518-8","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"2221_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamacardio.2019.1176","volume":"4","author":"MA Hofmann Bowman","year":"2019","unstructured":"Hofmann Bowman MA, Eagle KA, Milewicz DM (2019) Update on clinical trials of losartan with and without \u03b2-blockers to block aneurysm growth in patients with marfan syndrome: a review. JAMA Cardiol 4(7):702. https:\/\/doi.org\/10.1001\/jamacardio.2019.1176","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2221_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","volume":"62","author":"A De Paepe","year":"1996","unstructured":"De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE (1996) Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62(4):417\u2013426. https:\/\/doi.org\/10.1002\/(SICI)1096-8628(19960424)62:4%3c417::AID-AJMG15%3e3.0.CO;2-R","journal-title":"Am J Med Genet"},{"issue":"7","key":"2221_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jmg.2009.072785","volume":"47","author":"BL Loeys","year":"2010","unstructured":"Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47(7):476\u2013485. https:\/\/doi.org\/10.1136\/jmg.2009.072785","journal-title":"J Med Genet"},{"issue":"8","key":"2221_CR24","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.echo.2008.02.006","volume":"21","author":"MD Pettersen","year":"2008","unstructured":"Pettersen MD, Du W, Skeens ME, Humes RA (2008) Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 21(8):922\u2013934. https:\/\/doi.org\/10.1016\/j.echo.2008.02.006","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"issue":"8","key":"2221_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0002-9149(89)90430-x","volume":"64","author":"MJ Roman","year":"1989","unstructured":"Roman MJ, Devereux RB, Kramer-Fox R, O\u2019Loughlin J (1989) Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 64(8):507\u2013512. https:\/\/doi.org\/10.1016\/0002-9149(89)90430-x","journal-title":"Am J Cardiol"},{"issue":"21","key":"2221_CR26","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1161\/CIRCULATIONAHA.107.693523","volume":"117","author":"MG Keane","year":"2008","unstructured":"Keane MG, Pyeritz RE (2008) Medical management of Marfan syndrome. Circulation 117(21):2802\u20132813. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.693523","journal-title":"Circulation"},{"issue":"17","key":"2221_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJM199904293401702","volume":"340","author":"VL Gott","year":"1999","unstructured":"Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Pyeritz RE (1999) Replacement of the aortic root in patients with Marfan\u2019s syndrome. N Engl J Med 340(17):1307\u20131313. https:\/\/doi.org\/10.1056\/NEJM199904293401702","journal-title":"N Engl J Med"},{"issue":"6","key":"2221_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2001","unstructured":"Burnier M (2001) Angiotensin II type 1 receptor blockers. Circulation 103(6):904\u2013912. https:\/\/doi.org\/10.1161\/01.CIR.103.6.904","journal-title":"Circulation"},{"issue":"26","key":"2221_CR29","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1056\/NEJMoa070658","volume":"358","author":"BS Brooke","year":"2008","unstructured":"Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC (2008) Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome. N Engl J Med 358(26):2787\u20132795. https:\/\/doi.org\/10.1056\/NEJMoa070658","journal-title":"N Engl J Med"},{"issue":"3","key":"2221_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00007611-199303000-00012","volume":"86","author":"AC Tahernia","year":"1993","unstructured":"Tahernia AC (1993) Cardiovascular anomalies in Marfan\u2019s syndrome: The role of echocardiography and beta-blockers. South Med J 86(3):305\u2013310","journal-title":"South Med J"},{"issue":"1","key":"2221_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpeds.2006.09.003","volume":"150","author":"ES Selamet Tierney","year":"2007","unstructured":"Selamet Tierney ES, Feingold B, Printz BF, Park SC, Graham D, Kleinman CS, Mahnke CB, Timchak DM, Neches WH, Gersony WM (2007) Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. The J Pediatr 150(1):77\u201382. https:\/\/doi.org\/10.1016\/j.jpeds.2006.09.003","journal-title":"The J Pediatr"},{"key":"2221_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01534-3","author":"A Pitcher","year":"2022","unstructured":"Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, Wilson K, Reith C, Child AH, Clayton T, Dodd M, Flather M, Jin XY, Sandor G, Groenink M, Mulder B, De Backer J, Evangelista A, Forteza A, Baigent C (2022) Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: An individual patient data meta-analysis of randomised trials. The Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(22)01534-3","journal-title":"The Lancet"},{"issue":"9","key":"2221_CR33","first-page":"488","volume":"6","author":"P Dominiak","year":"1999","unstructured":"Dominiak P (1999) AT1-REZEPTORANTAGONISTEN: GIBT ES UNTERSCHIEDE? J f\u00fcr Kardiologie - Aust J Cardiol, 6(9):488\u2013494","journal-title":"J f\u00fcr Kardiologie - Aust J Cardiol,"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02221-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:05:03Z","timestamp":1697616303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02221-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02221-4","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed, performed and controlled according to current guidelines of Good Clinical Practice and approved by local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}